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Abstract  
Nanotechnology is an evolving scientific field that has allowed the manufacturing of 
materials with novel physicochemical and biological properties, offering a wide spectrum of 
potential applications. Properties of nanoparticles that contribute to their usefulness include 
their markedly increased surface area in relation to mass, surface reactivity and insolubility, 
ability to agglomerate or change size in different media and enhanced endurance over 
conventional-scale substance. Here, we review nanoparticle classification and their 
emerging applications in several fields; from active food packaging to drug delivery and 
cancer research. Nanotechnology has exciting therapeutic applications, including novel 
drug delivery for the treatment of cancer. Additionally, we discuss that exposure to 
nanostructures incorporated to polymer composites, may result in potential human health 
risks. Therefore, the knowledge of processes, including absorption, distribution, 
metabolism and excretion, as well as careful toxicological assessment is critical in order to 
determine the effects of nanomaterials in humans and other biological systems. Expanding 
the knowledge of nanoparticle toxicity will facilitate designing of safer nanocomposites and 
their application in a beneficial manner.  
KEYWORDS: nanotechnology; nanoparticles; nanotoxicology; nanomedicine; 
extracellular matrix  
Abbreviations: CNT, carbon nanotube; ECM, extracellular matrix; EGF, epidermal 
growth factor; ENM, engineered nanomaterial; FGF, fibroblast growth factor; GI, 
gastrointestinal tract; MWCNTs, multi-walled carbon nanotubes; NP, nanoparticle; NR, 
nanorod; PHA, polyhydroxyalkanoate; SWCNTS, single-walled carbon nanotubes.  
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1. Introduction  
The evolution of nanotechnology has resulted in a wealth of products containing or 
using nanomaterials with numerous potential applications. The small size of the particles 
imparts different properties to nanomaterials relative to those with larger sizes. Unusual 
physicochemical properties of engineered nanoscale materials (ENMs) are attributable to 
their small size, chemical composition, surface structure, solubility, shape, and aggregation 
(Nel et al., 2006). The term ENM is used to describe any manufactured substance at the 
nanoscale, which ultimately bestows on the substance characteristics and properties. An 
unequivocal definition of the term 'nanomaterial' is essential in the EU legislation and 
regulations, particularly taking into regard the management of potential risks of 
nanomaterials to human health and the environment. In October 2011, the European 
Commission published the Recommendation on the Definition of Nanomaterial, which 
defines nanomaterial as a natural, incidental or manufactured material containing particles, 
in an unbound state or as an aggregate or as an agglomerate and where, for 50% or more 
of the particles in the number size distribution, one or more external dimensions is in the 
size range 1nm-100nm (2011/696/EU). Innate and adaptive immune responses provide an 
efficient protection against invasion by foreign elements, not only for pathogens but also for 
nanomaterials. Subsequent to entrance into the body ENMs encounter the immune system 
and may induce desirable or undesirable immunological effects (Dumortier, 2013). At first, 
innate immune responses facilitate the participation of adaptive immune responses 
allowing the body to recognize foreign particles; later the adaptive immune system can 
produce signaling mediators which strengthen the effectiveness of innate immune 
responses (Wang et al., 2013).  
2. Nanoparticles Classification  
Recent studies classified nanomaterial types into separate categories (Habibi et al., 
2010; Yan et al., 2011) (Table 1):  
(i) By material: metallic (nanomaterials incorporating metals, transition metals, their 
compounds or composites, quantum dots, etc.); carbon (SWCNTs, MWCNTs, fullerenes, 
graphene, etc.); organic (agglomeration or assembly of organic molecules, biomolecules or 
bio-macromolecules, etc.); boron nitride;  
mineral (halloysite, etc.) and silicon (ii) By shape: quantum dots; aerogel; nanotubes; 
nanofibers; nanorods;  
nanoballs; nanosheets; nanowires and nanofibrils  
Primary uses of these defined nanomaterial types are to fulfill industrial applications, 
thus an overview of the behavior, therapeutic approaches and the current toxicity status of 
these compounds, is of great importance.  
2.1. Carbon Nanotubes  
Carbon Nanotubes (CNTs) possess several unique physicochemical properties that 
can result in various effects in organisms. The augmented surface area to size ratio leads 
to the tendency to aggregate, increasing interaction with biomolecules and as a result to 
higher surface reactivity (Firme and Bandaru, 2010; Fubini et al., 2010; Golokhvast et al., 
2015b). As mentioned above, surface chemistry and size play an important role in CNTs’ 
cytotoxicity. Indeed, it has been suggested that the cytotoxic response depends on the 
degree of functionalization and size, as shorter CNTs are less toxic than longer CNTs due 
to the ability of macrophages to engulf the former and thus be activated. The two most 
accepted proposed mechanisms of CNTs internalization are: (a) endocytosis/phagocytosis 
(b) nanopenetration. CNTs-exposed cells undergo oxidative stress due to the induction of 
oxidants and toxic enzymes. A higher level of oxidative stress leads to inflammation and 
cytotoxicity. Thus, decreased cell viability and elevated levels of the pro-inflammatory 
cytokines interleukin-8 (IL-8) and IL-1β are reported, while apoptosis may result from 
mitochondrial disruption and release of pro-apoptotic factors (Golokhvast et al., 2015a; 
Vitkina et al., 2016). Differential effects of single- (SWCNTs), double- and MWCNTs have 
been described. SWCNTs have been characterized as the most toxic type (Shvedova et 
al., 2005; Shvedova et al., 2012). In contrast, orally administered MWCNTs can induce cell 
reaction in the macula densa of the renal distal tubules and immunostimulating effects 
(Golokhvast et al., 2013).  
CNTs at various particle concentrations, even if they do not result in significant lung 
inflammation or tissue damage, cause alterations in systemic immune functions.  
Thus, immunosuppression caused by CNTs exposure is characterized by reduced T- 
cell-dependent antibody response as well as T-cell proliferative ability and increase in 
interleukin-10 (IL-10) and nicotinamide adenine dinucleotide phosphate [NAD(P)H] 
oxidoreductase-1 mRNA levels (Mitchell et al., 2007). Additionally, complement activation 
by CNTs is consistent with adjuvant effects and may also promote damaging effects 
through excessive complement activation. The first component of the classical complement 
pathway, C1q, binds directly and selectively to CNTs (Salvador-Morales et al., 2006). 
Actually, C1q also binds to immune complexes to elicit complement-dependent microbial 
killing and enhance phagocytosis (Lu et al., 2007). This interaction may influence the 
adhesion of CNT to phagocytic cells, while the excessive activation of complement can 
have a harmful effect on adjacent tissues (Rybak-Smith and Sim, 2011). Short-term 
inhalation of the rod-like CNTs induces novel innate immunity-mediated allergic-like airway 
inflammation in healthy animals. This is coupled with marked eosinophilia, mucus 
hypersecretion, airway hyper-responsiveness and the expression of Th2-type cytokines 
(Rydman et al., 2014). CNTs have various structures, which differ in the induction of 
immunological responses. Furthermore, the dispersion characteristic of SWCNTs is a 
dominant factor for the regulation of immunotoxic effects. Although, the low dispersion of 
SWCNT can suppress the activation of the inflammatory pathways and increase 
immunotoxicity, highly dispersed SWCNTs reduce this effect, which is related to the 
decrease of the T-cell population and lower level of immune function (Lee et al., 2015). 
Likewise, the short linear, thin bundles of SWCNTs elicit delayed pulmonary inflammation 
with slower recovery, while relatively long linear, thick bundles induce cellular immune 
activation and trigger acute lung inflammation shortly after inhalation (Fujita et al., 2015).  
MWCNTs are rapidly distributed to brain, liver and kidney via vascular transport 
(Albini et al., 2015). In addition, to stimulating the initiation of phagocytosis, MWCNTs 
cause the upregulation of CD14, CD11b, toll like receptor-4/ myeloid differentiation factor 2 
(TLR-4/MD2) and CD206, expression in macrophages. The macrophages that engulf 
MWCNTs secrete a large amount of macrophage inflammatory protein-1α (MIP-1α) and 
MIP-2 to recruit naive macrophages and release of angiogenesis-related cytokines matrix 
metalloprotease-9 (MMP-9) and vascular endothelial growth factor (VEGF). In this manner, 
the mixed status of M1/M2 macrophages supports angiogenesis (Meng et al., 2015). On 
the other hand, large MWCNTs agglomerates/aggregates, which are found in granulomas 
in the allergic rats, decrease serum IgE levels and the number of lymphocytes in 
bronchoalveolar lavage. This event indicates the modulatory action of MWCNTs in the 
allergy-associated immune response (Staal et al., 2014). Thus, the diverse abilities of CNT 
to impact the immune system should be taken into consideration for hazard assessment 
(Fujita et al., 2015; Rydman et al., 2014).  
2.2. Metal Oxide Nanoparticles  
Metal oxide nanomaterials are increasingly being used as catalysts with very wide 
industrial and commercial applications, especially as pigments and sunscreen ingredients 
for UV protection. Zinc oxide (ZnO) and titanium oxide (TiO2) NPs have proven to be more 
transparent compared with the normal-scale sunscreen particles; however, the potential 
toxicity of these NPs is not well understood. A variety of in vitro studies have been 
performed to assess the toxicity of several NPs using different cellular systems and tests 
(Donaldson et al., 2006; Hardman, 2006; Sayes et al., 2006). TiO2 NPs have been 
correlated with chromosome segregation, centrosome duplication, cytokinesis and 
functional regulation of mitotic checkpoint protein PLK1. Short-term exposure to NPs was 
reported to enhance cell survival, cell proliferation, ERK signaling activation and reactive 
oxygen species (ROS) production, while long- term exposure produces disturbances in cell 
cycle progression, chromosomal instability and cell transformation in cultured human 
fibroblasts (Huang et al., 2009; Rim et al., 2013). Such genotoxic effects are thought to be 
mediated through lipid peroxidation and oxidative stress mechanisms. On the other hand, 
the presence of ZnO NPs in human lung fibroblasts culture induced a concentration- and 
time- dependent increase in oxidative stress, intracellular Ca2+ levels and cell membrane 
damage. Alterations in gene expression due to oxidative stress and resulting apoptosis 
were considered to be the mechanisms for their cytotoxicity (Huang et al., 2010). 
Comparative studies performed for the evaluation of the relative toxicity of ZnO and TiO2 
NPs indicate that both NPs have a tendency to induce apoptosis- and necrosis-like cell 
death in human neural cells and in human fibroblasts, with ZnO NPs being more cytotoxic 
than TiO2 NPs (Lai et al., 2008).  
NPs rapidly interact with the proteins present in biological fluids. Thus, the coating 
proteins on the NP surface largely define the immunological identity of the particles 
(Cedervall et al., 2007). Despite the fact that metal oxide particles have similar surface 
charges in buffers, they bound different plasma proteins. TiO2 and ZnO NPs tend to form 
agglomerates in biological media and this leads to an increase bound of proteins, as 
immunoglobulins, lipoproteins, acute-phase proteins and proteins involved in complement 
pathways and coagulation, to these nanoparticles. (Deng et al., 2009). In vitro exposure of 
the TiO2 NPs, increase the expression of IL-6, IL-8, tumor necrosis factor-alpha (TNF-
alpha) and p53 genes in peripheral human lymphocytes (Baranova et al., 2015). On the 
other hand, the increase of neopterin production upon treatment of peripheral blood 
mononuclear cells (PBMC) with TiO2 NPs implies that these compounds induce pro-
inflammatory immune-regulatory pathways in T-cells and macrophages. The observation 
that the rates of tryptophan breakdown and interferon- γ (IFN-γ) production declined with 
increasing exposure to TiO2 materials indicate that TiO2 NPs target macrophages directly 
and that they have combined effects on promoting neopterin production and at the same 
time suppressing indoleamine 2,3-dioxygenase (IDO) activity.  
TiO2 NPs exert their cytotoxicity on the human macrophage and B lymphocyte cell 
lines dose- and size-dependently, via stimulation of the oxidative stress pathways (Becker 
et al., 2014). ZnO NPs induce a dose-dependent cell death and caspase activity in PBMC. 
ZnO but not TiO2 NPs induce a downregulation of CD16 expression on natural killer (NK)-
cells in the PBMC population, suggesting that subtoxic concentrations of ZnO NPs might 
have an effect on FcγR-mediated immune responses (Andersson-Willman et al., 2012). 
Nevertheless, the immunotoxicity of the ZnO NPs are contradictory. The variety of the size 
and charge causes differential effects on the immune system; the positively charged ZnO 
NPs exert higher cytotoxicity than the negatively charged ones in the murine macrophage 
cell lines (Kim et al., 2014a). ZnO NPs release free Zn ions that can be taken up by 
immune cells resulting in cell death. It was shown that the release of Zn ions from ZnO NPs 
triggers the production of excessive intracellular ROS, resulting in autophagic death 
(Johnson et al., 2015). Eventually, exposure to ZnO NPs can impair innate immune 
responses and attenuate macrophage responses to bacterial infection (Lin et al., 2014). 
Furthermore, inhalation of TiO2 NPs in rats was followed by an imbalance of Th1/Th2 
cytokines (Chang et al., 2014). Titanium accumulation in spleen and thymus caused 
histopathological changes and splenocyte apoptosis. Moreover, the exposure of TiO2 NPs 
could significantly increase the levels of MIP-1α, MIP-2, Monocyte Chemoattractant 
Protein-1 (MCP-1), vascular cell adhesion molecule-1 (VCAM-1), IL- 13, while it can 
markedly decrease the levels of NKG2D (Killer cell lectin-like receptor subfamily K, 
member 1) expression (Sang et al., 2014). Intratracheal inhalation of TiO2 NPs by rats 
significantly decreases the CD3+, CD4+, and CD8+ cells, while the ratio of CD4+ to CD8+ 
significantly increases, indicating a disturbance of cellular immune function (Chang et al., 
2015). However, the oral administration of TiO2 NPs results in significant increases in the 
levels of IL-12, IL-4, IL-23, TNF-α, IFN-γ and transforming growth factor-β (TGF-β) in the 
ileum of mice (Nogueira et al., 2012). When orally administered to mice, ZnO NPs caused 
a slight decrease in the CD4+/CD8+, indicating an alteration in the T-cell maturation and 
suppression of natural killer cell activity. Consistently, serum levels of pro/anti-inflammatory 
IL-1β, TNF-α, and IL-10, and IFN-γ, and IL-12 are also suppressed (Kim et al., 2014a).  
2.3. Metal Nanoparticles  
Metallic NPs, such as Ag, Au, Cu, and others, are widely used due to their 
antimicrobial properties. The toxicity of these NPs generally results from their chemical 
nature or from their dissolution products and/or agglomeration. In vitro studies revealed 
that Au and Ag NPs at concentrations between 5-100µg/ml were non-toxic to primary 
cultures of human bone marrow hematopoietic progenitor cells, while Co NPs caused 
toxicity in the same concentration range (Bregoli et al., 2009). The effects of metal oxides 
in in vivo models are different (Venkataramanan et al., 2016). The reactions of dermal 
structures to subcutaneous injections of Au- NPs were studied in CBA mice. It was 
demonstrated that injected NPs were phagocytosed by macrophages; some of them 
migrated to lymphoid follicles of the node, while others migrated into blood vessels. The 
endothelium was destroyed as a result of the toxic activity of macrophages loaded with 
metal NPs. The oxide compounds of metal NPs may exert their immunotoxic effects by 
releasing free ions that can be taken up by immune cells (Engin et al., 2012). Hence, the 
dose responses display maximum stimulation or biphasic dose–response relationship. The 
aggregation/agglomeration tendency of elemental metals and their oxides compounds 
(Borm et al., 2006) plays a potential role in their immunotoxicity which is evident by 
activation/dysregulation of macrophages and antigen presenting cells (APC) (Xia et al., 
2013). Even in nontoxic concentrations of nanosize, copper (II) oxide (Nano-CuO) particles 
cause a dose- and time-dependent increase in p38 phosphorylation-mediated plasminogen 
activator inhibitor-1 (PAI-1) expression due to oxidative stress (Yu et al., 2010). IgG is 
decreased by silver NP exposure, whereas IgM is increased. Immunoglobulin class 
switching from IgM to IgG requires T-helper cells and also APCs; therefore, IgG rather than 
IgM depends on the functional immune system, functionality is due to not only B-cells but 
also T-helper cells. In that manner, the effects of the silver NPs are likely exerted by the 
silver ions that are released from the NPs (Vandebriel et al., 2014). In addition, key factors 
contributing to toxicity are the size, shape, surface coating, surface charge, and conditions 
of silver ion release (Sharma et al., 2014). Thus, both the silver ions and TiO2 NPs 
increase the stimulation of the immune system and of apoptosis due to expression of IL-6, 
IL-8, TNF-α and p53 genes respectively under the effect of NPs, indicating that different 
forms of metal NPs may have similar immunotoxicity (Baranova et al., 2015). Furthermore, 
the smaller metal NPs induce significant immunotoxic effects at lower concentrations and 
shorter times. Ag NPs produces the following pro- inflammatory response: IL-1β 
expression preceding both TNF and prostaglandin E2 (PGE2) expression for 25 nm 
particles; and only significant TNF responses with no detectable PEG2 response for 40 and 
80 nm Ag NPs (Trickler et al., 2010). Moreover, exposure to metallic NPs causes increased 
oxidative injury mediated by cytokine regulation. The phagocytic function of alveolar 
macrophages is dose-dependently reduced by silver ions, ZnO, and TiO2 NPs. ZnO NPs 
induce greater cytotoxicity than the other NPs. Particle composition and chemical stability 
have primary roles in the immunotoxicity of different NPs.  
In some cases, the use of core-shell NPs consisting of metal and metal oxide 
provides the optimal combination of properties (Li et al., 2011). Depending on the 
production method, such NPs may have two, three or more layers. Core-shell NPs are 
produced through sequential synthesis by depositing a shell consisting of a metal or metal 
oxide on the surface of the NP cores that have been prepared in advance (Rudakovskaya 
et al., 2015). Often, due to the significant differences in the properties of the core and shell 
surface, it is necessary to use "crosslinking" materials in the form of polymers. The core-
shell NPs, the core of which consists of magnetite, have magnetic properties and they are 
of the greatest practical importance. Since grafting of ligands directly to the surface of 
magnetite is difficult, the latter is modified by applying metals that are capable of forming 
strong bonds with ligands. The core determines the magnetic properties of NPs, and the 
shell is used for the grafting of ligands at the same time, ensuring their stabilization and 
specific properties. The gold-coated magnetite particles are the most significant members 
of this category, and they are utilized for increasing the image contrast in magnetic 
resonance imaging (Wang, 2011), and as carriers for certain biomolecules and antibody 
sensors in immunoassays (Vickery et al., 2013). Another area of application is drug 
delivery and hyperthermia in cancer therapy (Widder et al., 1978). When injected the core-
shell NPs become opsonized and then rapidly captured from the vascular space by the 
liver, spleen and bone marrow macrophages (Reddy et al., 2012). Magnetite NPs are 
rather toxic and cause disruption of cell membranes, impair mitochondrial function, DNA 
damage, oxidative stress and a significant inflammatory response (Ahmad et al., 2012). 
Although it is believed that the magnetite NPs are not toxic at concentrations under 100 
µg/ml (Ahmad et al., 2012), these findings should be treated with caution. For instance, it 
has been reported (Berry et al., 2003) that magnetite NPs at a concentration of 50 µg/ml 
significantly reduced cell proliferation. However, coating the surface of magnetite with a 
layer of an inert metal, such as gold, can significantly reduce the toxicity of magnetic NPs 
(Chao et al., 2010; Salado et al., 2012). In addition, incubation of mouse fibroblasts with 
gold-coated magnetite NPs of 35 nm in diameter at concentrations below 1 mg/ml for 24 
hours showed more than 75% cell survival rate (Li et al., 2011). It was found that the 
magnetite-gold NPs at the concentration of 100 mg/ml resulted in hemolysis of only 1 % of 
cells when incubated for 1 hour with blood, and the median injected lethal dose in mice 
was found to be 8.39 g/kg body weight.  
2.4. Non-metal Oxide Nanoparticles  
Non-metal oxide SiO2 is widely used as additive to drugs, cosmetics, food, 
biomedical applications and biosensors. Exposure to SiO2 NPs results in a dose 
dependent cytotoxicity in cultured human bronchoalveolar carcinoma-derived cells that is 
closely correlated to increased oxidative stress. Specifically, increased ROS levels and 
reduced glutathione levels have been observed as well as increased production of 
malondialdehyde and lactate dehydrogenase release from the cells indicating lipid 
peroxidation and membrane damage (Lin et al., 2006). Moreover, these NPs caused an 
Nrf2-Erk-MAPK-induced expression of oxidative stress responsive transcription factor HO-
1, in human bronchial epithelial cells, Beas-2B, while a dysfunction of HUVEC was 
suggested via JNK, p53 and NF-κΒ pathways (Eom and Choi, 2009; Liu and Sun, 2010). 
Incubation with human plasma resulted in the formation of NP-biomolecular coronas 
enriched with immunoglobulins, complement factors, and coagulation proteins that bind to 
surface receptors on immune cells and elicit phagocytosis. Protein-coated NPs were 
protected from uptake by macrophages (Caracciolo et al., 2015). Actually, silica NPs do not 
aggravate human atopic dermatitis. However, when present in allergen-coated 
agglomerates, silica NPs lead to a low IgG/IgE ratio, a key risk factor of human atopic 
allergies (Hirai et al., 2015). Modified silica NPs with alkyne-terminated surfaces resist to 
agglomeration. Under certain conditions of T-cell activation, modified silica NPs enhance 
the proportion of antigen-specific CD8+ T cell responses. Various functional groups on 
modified silica NPs enhance IFN-γ and IL-2 production to different levels (Chen et al., 
2014).  
Silica NPs may cause immunotoxic effects that depent on their size and charge. The 
small-sized and negatively charged NPs have the most potent immunotoxicity by 
decreasing pro-inflammatory cytokine production, thus leading to immunosuppression (Kim 
et al., 2014b). In contrast, irrespectively of diameter size, silica particles induce caspase-1 
activation in macrophages (Kusaka et al., 2014). Other effects of silica NPs include ROS 
generation, the production of IL-6, IL-8, MCP- 1, TNF-α, IL-1β, and the enhanced 
expression of CD106, CD62E and tissue factor in human endothelial cells and monocytes. 
These suggest that interactions between particles, endothelial cells and monocytes may 
trigger or exacerbate cardiovascular dysfunction, atherosclerosis and thrombosis (Liu et al., 
2012). Silica NPs affect inflammatory response in dendritic cells by activating p38 and NF-
κB. The exposure of dendritic cells to ultrafine silica NPs decreases cell viability by 
inducing cell death in size- and concentration-dependent manner (Kang and Lim, 2012). 
The 30 nm and 50 nm silica-coated iron oxide NPs are taken up to a significantly higher 
degree through an active, actin cytoskeleton-dependent process with irrespective of size. 
On the other hand, upon administration of particles, macrophage or dendritic cell secretion 
of pro-inflammatory cytokines could not be detected (Kunzmann et al., 2011).  
2.5. Biopolymers  
Biopolymers are produced from various natural resources and crude oil. Four 
categories are recognized: a) biopolymers extracted directly from natural raw materials, 
such as cellulose, b) biopolymers produced by chemical synthesis from bio-derived 
monomers, such as polylactic acid (PLA), c) biopolymers produced by microorganisms or 
genetically modified bacteria, such as polyhydroxyalkanoates (PHAs), and d) biopolymers 
produced from crude oil, like aliphatic and aromatic polyesters, polyvinyl alcohol and 
modified polyolefins. Biodegradable PLA polymers are widely used in medical applications 
as surgical implants (Jain, 2000), tissue cultures and controlled release systems (Kuskov et 
al., 2010a; Kuskov et al., 2010b; Luu et al., 2003; Uhrich et al., 1999) as well as in active 
food packaging as an antimicrobials, because of their useful physical and mechanical 
characteristics (Jin and Zhang, 2008). In accordance to Regulation (EC) No. 1907/2006 
and Regulation (EU) No. 453/2010, short-term exposure to PLA may result in adverse 
health effects affecting the mucous membranes and respiratory system as well as the 
kidneys, liver and central nervous system. Long-term exposure to PLA may cause non-
allergic contact dermatitis and absorption through the skin. PHAs are a class of naturally 
occurring polyesters, consisting of over 100 different types of 3-hydroxy fatty acid 
monomers that are produced by a wide variety of microorganisms (Chen et al., 2015). 
Although they are derived biologically, the structures of these polymers are very similar to 
the structures of some synthetic absorbable polymers currently used in medical 
applications, especially for the development of tissue-engineered cardiovascular products 
(Li and Loh, 2015; Masood et al., 2014).  
The main categories of NPs, according to their dimensions and structural 
characteristics, are summarized in Table 1. These materials generate a minimal host 
inflammatory response and degrade into non-cytotoxic components. However high 
concentrations of the degradation products may have toxic effects.  
Polymeric biomaterials are selectively degraded by cell-generated ROS (Liu et al., 
2011). ROS-induced degradation of biodegradable polymers accelerates in vivo release of 
polymeric drug delivery systems (Knab et al., 2015). These polymeric particulate delivery 
systems are able to present antigens and induce pro- inflammatory cytokine production by 
activating both humoral and cellular responses (Nicolete et al., 2011). Nevertheless, 
poly(lactic-co-glycolic acid) (PLGA) particles have been extensively used as biodegradable 
delivery systems to achieve efficient uptake of protein-based materials, as well as major 
histocompatibility complex (MHC) class I cross-presentation and effective T and B cell 
responses. In this respect, NPs induce a balanced Th1/Th2-type antibody response (Silva 
et al., 2015). Furthermore, tolerogenic NP therapy is a potential novel approach for the 
treatment of immune diseases. Treatment with tolerogenic NPs results in inhibition of 
CD4+ and CD8+ T-cell activation, increase in regulatory cells, and durable B-cell tolerance 
resistant to multiple immunogenic challenges (Maldonado et al., 2015). A critical 
mechanism that induces persistent antibody responses is the activation of immune cells 
through TLRs or Nod-like receptors (NLRs). NLRs ligands encapsulated into poly- Lactic 
acid (PLA) NPs are efficiently taken up by human dendritic cells and subsequently strongly 
up-regulate maturation markers and enhance pro- inflammatory cytokine secretion by 
dendritic cells (Pavot et al., 2013). Furthermore, PLA NPs covalently couple with 
antibodies. Antibody-labeled NPs efficiently bind to cancer cells and produce ten-fold or 
higher signal (Nobs et al., 2006). Thus, IL-12 and TNF-α loaded PLA microspheres 
promote the systemic antitumor immunity and lead to the induction of specific anti-tumor T-
cells in the lymph nodes and spleens resulting in memory immune response (Arora et al., 
2006).  
3. The ADME Process 
Upon a substance entering the human body, either via external or internal exposure, 
the processes that follow the infection/intrusion are: absorption, distribution, metabolism 
and excretion. These are called ADME processes and constitute the subject of 
toxicokinetics (Fig. 1). A substance may enter the organism via medical intervention or 
dermal, oral as well as respiratory exposure. Therefore, toxicokinetics deals with the 
potential toxic effects of substances on the exposed tissues/organs. Although numerous 
ENMs have been manufactured, only a few studies exist in the field of ADME processes. 
To date, the majority of toxicokinetic studies deal with metals or metal oxide ENMs and to a 
lesser degree with polymer ENMs (Balani et al., 2005; Landsiedel et al., 2012).  
3.1. Absorption  
The nanospecific properties and characteristics of various ENMs are likely to affect 
their toxicokinetic behavior and toxicity profile. Skin is an important barrier that protects 
from environmental infection. It consists of two main structural layers: the epidermis and 
the dermis. The epidermis is the outer layer of the skin which has the role of the 
physicochemical barrier between the interior body and the environment. The outer layer of 
the epidermis (stratum corneum) covers the outside of the body and contains strongly 
keratinized dead cells (Bissett, 2009). Percutaneous absorption of substances follows the 
passing through this layer. On the other hand, the dermis is the deeper layer that provides 
the structural support of the skin. Several studies have focused on whether different drug 
formulations could penetrate into the skin after dermal exposure (Tinkle et al., 2003). The 
most unique particles are: liposomes, poorly soluble materials, such as TiO2 NPs, and 
submicron emulsion particles, such as solid lipid NPs (Hoet et al., 2004). As shown from a 
number of studies, skin absorption is size dependent. Indeed, in the case of TiO2 NPs that 
are used in sunscreen to protect skin from the UV light, nanosized particles are more likely 
to penetrate deeply in the skin layers (Andersson et al., 2002; Monteiro-Riviere et al., 2011; 
Nohynek and Dufour, 2012). Micro-sized liposomes do not easily penetrate into the 
epidermis, while those with an average diameter of 270 nm can reach the viable epidermis; 
smaller-sized liposomes can be found in higher concentrations in the dermis. Finally, 
biodegradable PLA used in transepidermal drug  
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delivery has been found to penetrate into 50% of the dysfunctional hair follicles. 
Indeed, in 12 to 15% of the follicles, the PLA particles achieved a maximal penetration 
depth which corresponds to the position of the sebaceous glands pores. These results 
suggest that particles based on PLA polymers may be useful carriers for hair follicle and 
sebaceous gland targeting (Rancan et al., 2009). There are limited data about the 
absorption of different ENM after dermal exposure and even lesser information on the 
transportation of the particles from the skin into systemic circulation. The journey of NPs to 
the targeted site of action is limited by many physiological barriers, one of them being the 
endothelial cells lining the lumen of blood vessels. The endothelial cells lining the lumen of 
blood vessels are a physiological barrier that controls the transportation of macromolecules 
and fluids from the blood to the interstitial space as well as the transfer of the NPs from the 
vasculature into target tissues. Water soluble particles cross more easily to the interstitium, 
a process facilitated by endothelial permeability and specific carriers (Mehta and Malik, 
2006). However, any disturbance in the endothelial system may lead to inflammation and 
subsequent loss of this function. Thus, the NPs by escaping from phagocytosis and directly 
interacting with the endothelial monolayer or getting phagocytized by the macrophages 
may provoke oxidative stress responses (Zhu et al., 2011). The endothelial lining of blood 
vessels differs in respect to its morphology and permeability in various organs (Pries and 
Kuebler, 2006). Most of the non- sinusoidal blood capillary walls permit the entrance of the 
lipid-insoluble endogenous and non-endogenous macromolecules up to 12 nm. Therefore, 
particles larger than the physiological upper pore size of the capillary walls limits do not 
accumulate within the respective tissues’ interstitial spaces (Sarin, 2010). The 
macromolecules are transported through the endothelium via transcellular and paracellular 
pathways. In healthy, non-inflamed vessels the paracellular permeability of the endothelial 
cell-cell contacts is limited, while caveolae is responsible for the transcellular transport from 
the blood to the perivascular interstitium. However, during the inflammation, the endothelial 
cell-matrix is disturbed and interendothelial cell-cell junction openings are increased, thus 
paracellular permeability is increased (Sun et al., 2011).    
The intestinal uptake of NPs has been more extensively studied and is better 
understood than pulmonary and skin exposure. For those NPs designed to stabilize food 
packaging or for drug delivery via intestinal uptake, it is possible to predict their behavior in 
the gastrointestinal (GI) tract. A substance that entered the human body after ingestion, as 
for example NPs that persist in the food matrix, may split in the GI tract. There are only a 
few data about the absorption of ENMs, but it is possible that they may not remain in a free 
form. Conversely, ENMs can agglomerate, become soluble, aggregate or react with some 
components of GI system, such as enzymes, intestinal microbiota or acids. Therefore, free 
form of NPs is going to be fully or partially lost. When NPs spilt in the GI tract there is a 
possibility for them to translocate through the intestinal wall. Translocation through the 
epithelium is a multistep process and depends on the properties of each nanomaterial such 
as surface area and charge, size, presence or absence of ligand and physiology 
characteristics of the GI tract (Maisel et al., 2015). The translocation of ENMs involves 
diffusion through the intestinal mucus, cellular or paracellular transport and contact with 
enterocytes or M-cells (Yun et al., 2013). Particles may pass through the GI lining via 
transcytosis by enterocytes, as observed in normal digestion, transcytosis by M-cells or by 
passive diffusion. The GI absorption of ENMs can also be affected by different surface 
coatings and surface charge, but these have been investigated to a lesser extent (des 
Rieux et al., 2006). Conclusively, ENMs studied up to date are not absorbed in a great 
extent in the GI tract. The amount of absorbed nanoparticles will then go through the portal 
circulation to the liver.  
3.2. Distribution  
After passing the GI tract, the absorbed ENMs can enter the capillaries and be 
transported to the liver or the lymphatic system through the portal circulation. The liver and 
the spleen are known to be the two major organs for systemic distribution of a large 
number of ENMs. However, certain ENMs may target all organs as demonstrated by their 
respective detection (Fig. 1). In addition, ENMs can interact with proteins and affect their 
tertiary structure leading to their dysfunction. This interaction could also lead to membrane 
expansion and cellular penetration, causing apoptosis in the exposed normal cells (Linse et 
al., 2007). Generally, it is acknowledged that ENMs of smaller sizes are more abundant in 
tissues as compared with larger-sized ENMs. The smaller particles are detected in kidney, 
liver, spleen, lungs and brain, while the larger particles remain inside the GI tract (Bergin et 
al., 2015). There is limited information about the distribution of injected and inhaled NPs 
and even fewer data about oral exposure. Irrespective of the uptake route, the distribution 
of NPs depends on the surface characteristics and the size of particles. Therefore, these 
are important issues to consider during drug design.  
3.3. Metabolism  
The metabolism (biotransformation) of ENMs via known routes (oral, inhaled, 
injected, dermal) depends, among others, on their surface chemical composition. The 
acidic environment of macrophages enhances dissolution of metal-containing particles as 
compared to neutral pH conditions (Arvizo et al., 2012; Pereira et al., 2015).  
Heavy metal-containing nanomaterials are widely used for clinical purposes. 
However, the charge of the particle coating as well as the hydrodynamic diameter (HD) 
play an important role in the adsorption of serum proteins (Choi et al., 2007). Thus, HD is a 
determinant during the production of clinically applicable nanoagents. Although neutral 
colloidal semiconductor nanocrystals quantum dots do not bind serum protein, it is not 
possible to synthesize them with an HD that allows them freely pass through the 
endothelial barrier (Uyeda et al., 2005). Zwitter ionic- coatings make the NPs more 
biocompatible. After the entrance of the NPs to the physiological environment, they readily 
wrapped up with protein corona which is the essential dictator of the fate, transport and 
toxicity of the nanomaterial in the host system (Ding et al., 2013). This may affect the 
internalization and clearance of the NPs by the immune cells for modulation of their further 
actions (Wang et al., 2013). On the other hand, the conformational changes of the proteins 
that coat the NPs may induce immune response (Nel et al., 2009). When the NPs are 
coated with antibodies for VCAM-1 and E-selectin in equal proportions, a more uniform 
vascular distribution is achieved (Hossain et al., 2014).  
SWCNTs were shown to be catalytically biodegraded over several weeks by the 
plant-derived enzyme, horseradish peroxidase. However, it has not been  
investigated yet whether peroxidase intermediates that are generated into the human 
cells or biofluids are involved in the biodegradation of CNTs. It has been shown that 
hypochlorite and reactive radical intermediates of the human neutrophil enzyme 
myeloperoxidase catalyze the biodegradation of SWCNTs in vitro, in neutrophils and to a 
lesser degree in macrophages. Importantly, the biodegraded nanotubes do not generate an 
inflammatory response when aspirated into the lungs of mice (Kagan et al., 2010).  
3.4. Excretion  
Up to date there is limited information about the excretion of NPs. The limited data 
available indicate that insoluble ENMs may remain in the tissues after exposure for long 
periods and accumulate. No evidence exists on the presence of ENMs in the milk (The 
EFSA Journal, 2009).  
4. Nanoparticles and their applications  
Like other major technological advances, nanotechnology offers novel advantages 
and challenges, especially when applied to the medical and food-related products 
regulated by the Food and Drug Administration (FDA). The unique chemical and biological 
properties of nanomaterials make them useful in many products for human uses, including 
those in industry, agriculture, business, medicine, clothing, cosmetics and food 
(Oberdorster et al., 2005a; Oberdorster et al., 2005b) (Fig. 2).  
4.1. Therapeutic Delivery Systems  
Drug or gene delivery is a very promising application for NPs. The primary research 
goal of therapeutic delivery includes high specificity for both drug targeting and delivery. 
The second goal is the reduced toxicity, while therapeutic efficacy is maintained. Therefore, 
the utilized NPs have to be well characterized in terms of their toxicity before their clinical 
use. NP carrier systems must be biologically safe and biocompatible in order to avoid the 
adverse effects derived from the interactions among NPs and living cells (Hossain et al., 
2011). Indeed, there are many advantages arising from the use of nanobased drug delivery 
systems (Emerich and Thanos, 2007; Groneberg et al., 2006; Petrochenko et al., 2015). 
These include improved solubility, prolonged drug circulation lifetime, reduced 
immunogenicity and specific and selective drug delivery with minimum side effects. 
Moreover, drug delivery systems are characterized by the ability of combined therapy and 
drug resistance suppression, applying two or more drugs during drug release. Therefore, it 
is clear that the NPs-based drug delivery is a promising approach with a number of 
compositions under clinical trials (Zhang et al., 2008). The novel properties of 
nanomaterials offer them the opportunity to be used as drug delivery carriers as well as 
diagnostic probes. The utilization of NPs in this sector gives the opportunity for targeted 
drug delivery with the minimum toxic effect, in order to deal with several diseases 
(Bawarski et al., 2008).  
4.2. Applications in Chronic Diseases  
NPs have made a tremendous impact in the treatment of ocular, neurodegenerative 
and respiratory diseases, as well as HIV/AIDS and cancer, as shown by the numerous NP-
based drugs and therapeutic delivery systems that are already in clinical use (Fig. 2). 
Indeed, the utilization of molecules such as DNA, RNA and proteins in drug development is 
restricted as they do not have the ability to enter the cells through passive diffusion. 
Therefore, their interaction with NPs is required to enable effective delivery. Manipulating 
polymer- (Kuskov et al., 2010b) and liposome-based drug delivery nanodevices, gives 
scientists the opportunity to focus on their properties and use them for the benefit of clinical 
medicine (Hossain et al., 2011; Kuskov et al., 2010a; Kuskov et al., 2010b).  
4.3. Improving Cancer Treatment Strategies  
Currently, the use of NPs in cancer treatment includes dendrimers, liposomes, 
polymeric NPs, polymeric micelles, protein NPs, nanocrystals, viral NPs, metallic NPs as 
well as CNTs. These systems have been evaluated for their suitability of their application 
for in vivo cancer imaging and treatment (Byrne et al., 2008; Cho et al., 2008; Hahn et al., 
2011). Recent advances have led to the development of bioaffinity NP probes for molecular 
and cellular imaging, intracellular targeting, targeted NP drugs for cancer therapy and 
integrated nanodevices for early screening and cancer diagnosis (Jabir et al., 2012; Ruan 
et al., 2015; Yang et al., 2015a; Zhu et al., 2015).  
Cancer nanotechnology is a rapidly growing field that has made a remarkable 
contribution to treatment strategies by enabling selective and specific release of 
chemotherapeutic agents based on their physicochemical and biological properties (Cho et 
al., 2008; Ranganathan et al., 2012). Various approaches have been applied for the use of 
nanomaterials in cancer treatment. Targeted drug delivery system via nanocarriers reduces 
tumor growth and related tumor events, such as angiogenesis and metastasis without 
damaging healthy tissues (Byrne et al., 2008; Ranganathan et al., 2012). An alternative 
approach is the targeting of the tumor cell via ligand- mediated specific interactions 
between NPs and cancer cell surface. The respective ligands may be growth factors, 
cytokines and antibodies (monoclonal and artificially engineered antibodies or antibody 
fragments) that facilitate the uptake of carriers into target cells (Alexis et al., 2008; 
Kontermann, 2006; Puri et al., 2008). Nanotherapeutics is effective in the targeting of the 
tumor microenvironment, which is characterized by enhanced permeability and retention 
(Fang et al., 2011). Finally, progress has been accomplished in the targeting of recurrent 
and drug resistant cancers, even though this approach is often limited by the lack of 
specific ligands. It has been reported that targeting of metastatic colon cancer cells is 
possible using a PEGylated liposome modified with a fibronectin-mimetic peptide (Garg et 
al., 2009). Moreover, PEG has been demonstrated to be a safe carrier for inhalational 
agents (Zarogoulidis et al., 2012a). Indeed, directed cell targeting has been the focus of 
several scientific groups. Alveolar macrophages are found to be the vehicle to deliver a 
chemotherapeutic agent to the lymph nodes through the lymphatic circulation. Moreover, 
intracellular targeting is used to improve drug efficiency, while focusing on specific cellular 
parameters (Ranganathan et al., 2012; Tarhini et al., 2013), including intracellular 
trafficking, endosomal release and nuclear localization (Goren et al., 2000; Lundberg et al., 
2003; Zarogoulidis et al., 2012a; Zarogoulidis et al., 2012c).  
It has been reported that certain delivery systems have the ability to deliver their 
entire drug cargo to patients without any loss to the environment, such as toxins release 
(Wittgen et al., 2006; Zarogoulidis et al., 2012b). However, further evaluation is needed 
regarding the use of these investigational strategies. Clinical trials have shown that the 
lipophilic diterpenoid paclitaxel has antineoplastic activity, particularly against primary 
ovarian epithelial carcinoma, breast, colon, head and neck cancers and non-small cell lung 
cancer (Cai et al., 2012). Nanodevices offer the opportunity to achieve targeted delivery of 
paclitaxel, a commonly used chemotherapeutic agent in cancer treatment, to tumor sites. 
PEGylated liposomes conjugated with truncated fibroblast growth factor receptor, a 
receptor found in many tumor types, are designed to achieve prolonged circulation time in 
the bloodstream and enhanced accumulation of paclitaxel in tumor tissues. These benefits 
may improve the therapeutic efficacy of paclitaxel as well as the promising potential as a 
long-circulating and selective tumor-targeting delivery system (Cai et al., 2012; Guo et al., 
2015).  
Nab-paclitaxel is a novel albumin-bound nano-formulation of paclitaxel that enables 
higher intra-tumoral drug concentrations to be achieved (Desai et al., 2006). Antitumor 
activity of nab-paclitaxel is enhanced over solvent-based paclitaxel, whereas its toxicity 
profile is distinct to paclitaxel. Nab-paclitaxel has proven clinical benefit and is currently 
approved in both the US and Europe as monotherapy in metastatic breast cancer, in 
combination with gemcitabine in advanced pancreatic cancer, and in combination with 
carboplatin in the first-line treatment of advanced non-small cell lung cancer (Gradishar et 
al., 2005; Socinski et al., 2012).  
The delivery of DNA or RNA to cells represents a limiting step in the development of 
cancer gene therapy and RNA interference protocols for intracellular targeting. SWCNTs 
are of interest as carriers of biologically active molecules because of their ability to cross 
cell membranes. In a recent study, a novel strategy has been reported for chemical 
functionalization of SWNTs in order to bind small interfering RNA (siRNA) by disulfide 
bonds when applying to siRNA-mediated gene silencing in breast cancer cells. This 
approach has led to the efficient inhibition of breast cancer cells’ proliferation (Chen et al., 
2012). Moreover, intracellular targeting via siRNA delivery through endocytosis is of great 
importance. Thus, applying biocompatible siRNA- carbonate apatite NPs complexes, in a 
pH-sensitive environment, leads to an efficient gene transfection, intracellular targeting and 
an effective knockdown of functional cancer genes resulting ultimately in cancer cell death 
(Hossain et al., 2011; Hossain et al., 2010).  
4.4. Synthetic Extracellular Matrices: Multipurpose Nanoscaffolds  
The natural extracellular matrices (ECMs), which support cells in tissues, are mostly 
composed of proteoglycans, glycosaminoglycans, adhesion molecules, collagen fibers as 
well as various signaling molecules (Barbouri et al., 2014; Theocharis et al., 2014; 
Tzanakakis et al., 2014). Synthetic ECMs must be capable of mimicking endogenous 
human tissue ECMs in order to support tissue regeneration or replacing (Lee et al., 2014a; 
Wang et al., 2014). Thus, synthetic ECMs must exhibit mechanical and tensile 
characteristics, identical to those of natural ECMs and simultaneously be nontoxic and non-
immunogenic (Tonelli et al., 2012). Indeed, there is a focused effort to use nanostructured 
biomimetics as nanoscaffolds modulated at the molecular level. Thus, scaffold topography 
mimics the native ECMs in terms of framing, porosity and bio-functionality (Singh et al., 
2014). In recent years, CNTs and their applications became attractive as materials for 
artificial bone development and bone regeneration due to their biocompatibility, 
biodegradability, physicochemical stability, mechanical strength as well as low 
immunogenicity (Karahaliloglu et al., 2015; Silva et al., 2009). The nanotubes are 
chemically inert, but upon chemical modification, they can be conjugated with collagen, 
bestowing them the ability to form efficient scaffolds for cell growth in 3D arrays (Hopley et 
al., 2014). High degree of flexibility and porosity (Shokrgozar et al., 2011), interaction with 
proteins and DNA (Li et al., 2012) and large contact surface area, are some of the CNTs 
features that are common with the natural ECM components.  
Successful tissue engineering requires several obligatory components: a 
biocompatible ECM, suitable cells, a medium containing cytokines and a bioreactor 
(Padmanabhan and Kyriakides, 2015; Raftery et al., 2015; Sikavitsas et al., 2002). A 
synthetic scaffold, composed of variously functionalized CNTs and collagen fibers was 
found to be a promising substitute for natural ECM. CNTs increase the strength and 
regulate the orientation of collagen fibers, which results in scaffolds’ increased stability and 
bioactivity. Subsequently, the artificial scaffold is combined with suitable progenitor cells in 
order to support their growth and specific differentiation to mature cell types e.g. 
osteoblasts, osteoclasts and muscle cells (Silva et al., 2009). In vivo, the scaffold is 
gradually biodegraded, as proliferation and differentiation of implanted cells continue, 
allowing contact of implanted cells with host blood vessels. The desired end-result is the 
normal function of the regenerated tissue (Suck et al., 2010).  
In a different approach, gold (Au) NP embedded nanofibrous scaffold of FDA 
approved polycaprolactone (PCL), Vitamin B12, Aloe Vera and Silk fibroin (SF) was 
constructed to induce the differentiation of mesenchymal stem cells into cardiac lineage 
cells in order to obtain the regeneration of infarcted myocardium. The gold NP blended 
PCL scaffolds were found to support MSCs proliferation and differentiation into 
cardiomyocytes. The appropriate mechanical strength provided by the functionalized 
nanofibrous scaffolds supported the MSCs to produce contractile proteins and achieve 
typical cardiac phenotype (Sridhar et al., 2015). Importantly, silk fibroin due to its excellent 
biocompatibility is a candidate material to replace collagen. Indeed, membrane-reinforced 
three-dimensional electrospun silk fibroin scaffolds were shown to support the growth of 
human osteoblasts in a manner superior to collagen scaffolds and to increase the bone 
tissue formation in rat calvarial defect models (Yang et al., 2015b). Hydrogels are known to 
possess high water content and to resemble the microenvironment of extracellular matrix. 
Magnetic NPs were incorporated into a hybrid hydrogel containing type II collagen, 
hyaluronic acid (HA), and polyethylene glycol (PEG) to produce a magnetic nanocomposite 
hydrogel (MagGel) for cartilage tissue engineering. The MagGel could travel to the tissue 
defect sites in physiological fluids under remote magnetic guidance and support bone 
marrow derived mesenchymal stem cells adhesion and survival exhibiting potential for 
cartilage tissue engineering application (Zhang et al., 2015). Moreover, natural 
polysaccharides were found to enhance chondrocyte adhesion and proliferation on 
magnetic NP/PVA composite hydrogels suggesting that magnetic composite NPs and 
polysaccharides provide synergistic facilitation of cell adhesion and growth (Hou et al., 
2015). The participation of natural polysaccharides (HA and CS) in the creating of 
nanostructured biomimetic scaffold system in the form of micro-porous polycaprolactone 
(PCL) spiral structure decorated with sparsely spaced bioactive PCL nanofibers, was 
reported to enhance the differentiation of the rat bone marrow stem cells (rBMSCs) into 
chondrogenic lineage in vitro (Lee et al., 2014b). The formation of a bi-layer scaffold of 
chitosan/PCL-nanofibrous mat and PLLA-microporous disc for keratinocyte and fibroblast 
co-culture provided a microenvironment similar to those present in the native ECM during 
initial wound healing (Lou et al., 2014). Moreover, layer by layer self-assembling of 
polysaccharide- coated BSA NPs on Ti surfaces resulted in nanostructured architectures 
which created cellular microenvironments mimicking natural ECMs (Wang et al., 2015).  
4.5. Nanotechnology in Stem Cell Research  
The incorporation of stem cells into CNTs gives them the ability to proliferate and 
differentiate into various cell types. Cells utilized in tissue engineering are progenitor cells 
arising from bone marrow that can be directly injected to injured tissues cultured in vitro, or 
be conjugated with the scaffold and then used to regenerate tissues (Bianco and Robey, 
2001). However, further investigation is needed to elucidate the biological impact of CNTs 
on stem cells. The improvement of cellular responses by creating an appropriate nano-
biointerface, the enhancement of scaffolds bioactivity as well as the improvement in 
delivery of bioactive molecules, could lead to optimization of nanofibrous materials for 
tissue engineering and other clinical applications (Ilie et al., 2012).  
4.6. Applications in Food Industry and Related Areas  
Nanotechnology can also be applied to all phases of the food cycle. Food packaging 
is one sector of the industry where nanotechnology applications and synthesis of 
nanomaterials are rapidly expanding (Fig. 2). Modern food packaging started in the 19th 
century with the invention of canning by Nicholas Appert. The introduction of plastics as 
food packaging materials started one century later and its application is under continuous 
development. Indeed, during the last decades, the innovations are correlated with polymer 
nanotechnology and they are characterized by novel properties. Even though the novel 
properties of ENMs make them attractive in food packaging applications, safety issues may 
occur, different from those raised by conventional-scale version of the same material 
(Fubini et al., 2010). The basic categories of nanotechnology applications in the 
development of food packaging include: the manipulation of polymer barriers, the 
improvement of active components that can protect food and/or deliver functional attributes 
and the design of smart packaging materials that can facilitate the transduction of relevant 
information. As regarding improved food packaging, NPs improve the packaging properties 
of the polymer. Barrier properties are perhaps one of the most important and challenging 
components of food packaging. The penetration of light, moisture or gases can alter the 
sensory characteristics of food products, as well as induce possible dangerous spoilage 
(Marsh and Bugusu, 2007; Sekhon, 2010). Whereas many other applications of 
nanotechnology are still destined for the future, nanocomposites that enhance barrier 
properties are already commercially available. Nanoclays and CNTs demonstrate 
improvements in the structural, thermal, barrier and flame-retardant properties of plastics, 
while CNTs also enhance electrical conductivity. In active food-packaging, the presence of 
NPs allows package materials to interact with food and environment, which is important for 
food preservation. Antioxidants, O2 scavengers, antimicrobial agents and humidity 
regulators are some of the including characteristics of the active packaging, that give the 
characterization of antimicrobial activity of nanocomposites included in food packaging 
(Sondi and Salopek-Sondi, 2004). Another important application of nanomaterials in this 
type of food packaging is the degradation of ripening gas, such as ethylene (Maneerat and 
Hayata, 2006). The presence of nanocomposites in smart food packaging can monitor the 
condition of packaged food or the environment surrounding. These novel materials are 
called nanosensors and they are able to respond both to environmental changes, such as 
temperature, humidity and oxygen levels in storage rooms, and to indicate degradation 
products or microbial contamination via oxygen indicators and pathogen sensors. 
Nanosensors are also designed to give information about the enzymes produced in the 
breakdown of food substances, making them unsafe for human consumption. There are 
also some devices, offered for the consumer’s services on the basis of intelligent 
preservative-packaging technology, which will be capable of releasing a preservative if 
contained food begins to spoil (Duncan, 2011; Sekhon, 2010). Different types of functional 
nanostructures can be used to create materials with novel properties and introduce new 
functionalities in the food industry. They include nanoclays, carbon NPs, nanoscale metals 
and oxides and polymeric resins. These manufactured substances provide improved 
strength, temperature and moisture stability, reduce weight and can be used as barriers 
against O2, CO2, moisture, UV radiation and volatiles of packaging materials. For 
example, CNTs can be used in food packaging to improve its mechanical properties. It has 
been recently reported that CNTs exhibited powerful antimicrobial effects when applied 
directly or through aggregates of CNTs. Chitosan-based films, have been shown a 
promising range of antimicrobial activity (Rhim et al., 2006). Another important field of food 
packaging nanotechnology is the protection of some nutrients such as vitamins, 
antioxidants, proteins, carbohydrates and lipids. This can be achieved using the techniques 
of nanoencapsulation, where the final product will be characterized by improved 
functionality and stability. Scientists have designed some lipid-based nanoencapsulation 
systems that enhance the antioxidant activity by improving their solubility and 
bioavailability, while preventing undesirable interactions with other food components. The 
main system in this category is nanoliposome technology where nanoliposomes can be 
used as carrier vehicles of bioactive compounds, nutraceuticals, enzymes, food additives 
and food antimicrobials (Mozafari et al., 2008).  
5. Nanoparticles: Cytotoxic Aspects  
Although NPs primarily target the respiratory system, other organs, such as the GI 
tract, can also be affected. NPs can enter GI tract via different routes, e.g. indirectly via 
mucociliary movement or directly via oral intake of water, food, cosmetics and drug delivery 
systems in nanoscale. Nanotoxicology is the science that studies the nature and the toxic 
effects of nanoscale particles and composites on humans and other biological systems 
(Donaldson et al., 2004; Feron and Groten, 2002; Xu et al., 2011). So far, there is limited 
knowledge concerning the toxicological effects of NPs. However, several authors 
confirmed that the toxic behavior of NPs differs from their bulk counterparts. Even if NPs 
have the same chemical composition, they differ in their toxicological properties, while the 
difference in toxicity depends on size, shape, reactivity, surface charges and types of 
coating. Therefore, before NPs are commercially used, a toxicity evaluation is important 
(Kumar et al., 2012). When a nanostructure enters the human body, via external or internal 
exposure, the processes that follow the infection are: absorption, distribution, metabolism 
and excretion, known as the ADME processes (Fig. 1).  
During ADME, any interaction with biological systems can give rise to various 
cytotoxic effects, including chemical allergy, fibrosis, organ failure, cytotoxicity, tissue 
damage, ROS generation and DNA damage (Corsini et al., 2013; Golokhvast et al., 2015a; 
Nel et al., 2006; Singh et al., 2009). These data are summarized in Table 2.  
5.1. Nanoparticle Interactions with Extracellular Matrix Biomolecules  
The complex ECM networks not only provide essential physical scaffolding to the 
cells in tissues, but also initiate crucial biochemical and biomechanical signals that are 
required for tissue morphogenesis, differentiation and homeostasis (Karamanos, 2014; 
Skandalis et al., 2014b; Theocharis et al., 2015). Thus, the cell-ECM interface modulates 
signaling cascades which regulate almost all aspects of cell behavior (Afratis et al., 2012; 
Bouris et al., 2015; Gialeli et al., 2011; Gialeli et al., 2013; Theocharis et al., 2014). 
Importantly, the ECM is remodeled during the onset and development of different 
pathologies and these alterations contribute to disease progression (Gialeli et al., 2014; 
Nikitovic et al., 2013; Nikitovic et al., 2015). Thus, the interactions of NPs at the ECM-cell 
interface need to be examined to cover safety concerns and health issues. It has been 
demonstrated that many NPs, such as CNTs, have the ability, by engaging various 
mechanisms, to interact with and penetrate cell membranes and consecutively locate to the 
cytoplasm, sub-cell organelles as well as to the nucleus. At these locations the NPs may 
interfere with various signaling pathways and therefore affect cell behavior (Zhao and Liu, 
2012). An important possible consequence of NPs and ECM interactions is the production 
of ROS and the resulting oxidative stress. It has been reported that the ROS dependent 
modulations of ECM critically affect human cells’ biological functions, while imbalances in 
ROS levels are strongly correlated with the complex process of tumor progression 
(Nikitovic et al., 2013; Nikitovic et al., 2014). Moreover, a recent study revealed that 
nanoformulations of the glycosaminoglycan heparin, apart from their anticoagulant action, 
exhibit anticancer activity as well. Importantly, nano-heparin derivatives are capable to 
significantly reduce breast cancer cell proliferation and to regulate the expression profile of 
major ECM macromolecules, providing strong evidence for therapeutic targeting (Belmiro 
et al., 2009; Cardilo-Reis et al., 2006; Piperigkou et al., 2015). An example of the 
deleterious ECM-NP interactions was the finding that the titanium-wear particles, formed at 
the bone-implant interface, induce osteoblast –dependent ECM remodeling that is 
responsible for aseptic loosening, which is a main cause of total joint replacement failure 
(Xie et al., 2015).  
The ability of living cells to recognize and respond to chemical and physical stimuli in 
their surrounding is fundamental for cell survival. Signal transduction, typically driven by 
growth factors or cytokines, is the main mechanism that cells use to convert an external 
signal to cellular outcome. The bioavailability of growth factors is largely determined 
through their interactions with ECM molecules and cell membrane receptors (Moskowitz et 
al., 2012; Skandalis et al., 2014a). It has been shown that epidermal growth factor and its 
specific receptor, EGFR, control the activation of numerous signaling pathways, including 
the phosphoinositide 3- kinase/Akt pathway and the Ras/Erk cascade, which results in an 
up-regulation of the gene transcription necessary for cell proliferation, survival and 
migration (Riese and Stern, 1998). A recent study has shown that metallic NPs altered 
EGF-dependent signal transduction in the human epithelial cell line A-431, through 
downstream PI3K/Akt and Ras/Erk cascades and thus, affected these cells’ immune and 
inflammatory responses and cell proliferation. Specifically, after internalization, Ag- NPs 
drastically increased ROS production, followed by attenuation of Akt and Erk signaling. Au-
NPs significantly diminished p-Akt and p-Erk levels whereas Fe-NPs strongly modulated 
EGF-dependent gene transcription (Comfort et al., 2011). PI3K and Akt signaling cascades 
in addition to EGF effects are triggered via integrin- dependent mechanisms in order to 
respond to extracellular stress (Abraham, 2005; Alenghat and Ingber, 2002; Attwell et al., 
2000). The activation of Akt by EGF-R and β1-integrins is an important component of 
adhesion-dependent signaling. A recent study has shown that CNT-induced epithelial cell 
proliferation is mediated by the activation of PI3K and Akt, indicating a specific signaling 
mechanism (Unfried et al., 2008). An in vitro study demonstrated that when the widely used 
in biomedical applications, gold nanorods, AuNRs, are modified with polyelectrolyte 
multilayers they interact directly with collagen type I, altering the polymerization and 
mechanical properties of this important ECM component, which lead to a diminished ability 
of cardiac fibroblasts to contract collagen gels (Wilson et al., 2009).  
6. Conclusions  
Nanotechnology has a wide spectrum of applications to medicine (“nanomedicine”) 
that include screening of early disease, treatment for advanced disease and assessment of 
therapeutic outcomes. In this context drug delivery carriers as well as NP-based imaging 
probes in the treatment of cardiovascular disorders, ocular, neurodegenerative, respiratory 
diseases and AIDS, enhancement of wound healing, selective and specific release of 
chemotherapeutic agents for cancer, artificial bone development and bone regeneration, 
cellular microenvironments mimicking natural ECMs are very promising applications for 
NPs.  
Although the NPs are roughly categorized by their material and shape, 
physicochemical diversities should be considered. Therefore, further studies on 
nanotoxicity as well as toxicological assessments are necessary in order to determine the 
effects of NPs in biological systems. Initially, physiological barriers control the translocation 
of the nano-sized particles between the blood and interstitial space. Later, despite of the 
differences in their material compositions, NPs provoke oxidative stress in tissues. Thus in 
CNTs-exposed cells, a higher level of oxidative stress leads to inflammation and 
cytotoxicity, while metal oxide NPs exert their genotoxic effects through lipid peroxidation. 
However, they rapidly interact with the proteins in the biological fluids to form protein 
corona leading to the alteration in their behavior. Furthermore, metal NPs have biphasic 
dose-response relationship. Their oxidative damage causes disruption of cell membranes 
and mitochondrial dysfunction. On the other hand, non-metal oxide NPs cause ROS 
generation, whereas biopolymers generate a minimal host inflammatory response and 
degrade into non-cytotoxic components.  
Recently, European Commission reports included the information considering current 
regulatory requirements under environmental legislation and provided a series of 
recommendations to improve the knowledge base on exposure, required for adequate risk 
assessment of nanomaterials. In this context, introducing innate and adaptive immune 
responses induced by nanomaterials will clarify desirable or undesirable immunological 
effects of ENMs and will be guidance for thematic studies. This is considered to be a 
growing and promising research area which is going to deepen our understanding of the 
cellular mechanisms of NP actions and their effect on functional cell properties related with 
human disease. Thus, further investigations are needed to explore the nano-bio interface, 
immune responses, optimization of nanomaterial utilization for tissue engineering, clinical 
applications, and the food industry.  
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Table 1: Classification scheme of ENMs. According to their dimensions, structure and 
surface chemical modifications, NPs are organized into three major groups: a) solid NPs; 
b) lipid-based vehicle nano-systems, and c) polymeric-based vehicle nano- systems. Main 
applications of each NP type are also depicted. Adapted by (Champion et al., 2007; Geilich 
et al., 2015; Letchford and Burt, 2007; Liu et al., 2013).  
Table 2: Possible toxic effects of nanomaterials as pathophysiological outcomes. 
Adapted by (Nel et al., 2006).  
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Figure 1: Schematic presentation of the ADME process. When NPs enter the human 
body, through various exposure ways (such as skin and inhalation), the following 
processes include absorption, distribution, metabolism and excretion. When translocated in 
the gastrointestinal tract, NPs are transformed into their free forms and absorbed through 
the liver and/or the lymphatic system. Then they are capable to present their different mode 
of actions, however, their possible health risks must be under case-by-case analysis.  
Figure 2: Schematic representation summarizing the emerging aspects of 
nanomaterials in health and disease. According to the European Commission 
Recommendation, nanomaterial contains particles with one or more external dimensions in 
the size range 1-100 nm. NPs offer new benefits and challenges with their applications in 
consumer, food-related and medical products. Nanomedicine specializes in fields including 
therapeutic targeting, drug delivery systems and cancer focused therapeutic approaches. 
However, at all costs, NPs toxicological effects must be evaluated in order to serve as 
beneficiary and safe agent in commercial applications.  
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Table 1  
   
Particle shape and dimensions  
 
Description  
  
  
Applicati
ons  
   
Solid Nanoparticles  
  
10-100nm  
  
 
Spherical or 
solid particles with 
homogenous 
composition  
  
  
Opticoa
coustic 
tomography, 
catalytic 
activities  
   
 
350-450nm  
Tubular 
particles with 
homogenous 
composition  
Catalyti
c activities, 
high- capacity 
electrochemic
al capacitors  
  
60nm-30µm  
  
 
Complex non-
spherical particles  
with 
homogenous 
composition  
  
  
Drug 
delivery, 
microfluidics  
   
 
>100nm  
Particles of 
heterogeneous 
composition (variation 
between the same 
body and the surface)  
Industri
al catalysis  
   
 
Particles of 
heterogeneous 
composition (changes 
in the allocation of the 
  
Limited 
applications 
due to 
composition)  hazardous 
waste  
  
 
Homogeneous 
aggregations  
(consisted of 
different types of 
particles)  
  
  
Limited 
applications 
due to toxic 
effects  
   
  
Heterogenous 
aggregations  
(consisted of 
different types of 
particles)  
  
Ion 
batteries  
   
Lipid-based vehicle nano-systems  
  
70-100nm  
  
 
Nano-liposomes  
(lipid bilayer of 
transfer vehicle)  
  
  
Drug 
delivery, 
dietary and 
nutritional 
supplements, 
stabilizers  
   
  
Micelle  
(simple lipidic 
layer of transfer 
vehicle)  
Solubilit
y 
enhancement  
 
 
Nano-cochlea    
Formati
 
>5-100nm  
  
(the sheet of the 
lipidic layer wraps in 
a spiral form)  
  
on of 
fullerenes 
and nano-
onions  
   
Polymeric-based vehicle nano-systems  
 
100nm-10µm  
  
Micelle 
(agglomerated 
copolymers)  
  
Drug 
delivery  
   
 
100nm-10µm  
  
Nano-spherical 
particles  
(agglomerated 
copolymers produced 
in the solid main tank)  
  
Drug 
enzymatic 
protection  
   
 
250-450nm nano- & micro-scale  
Nano-
capsule/polymerosom
e  
(polymeric 
membrane 
surrounded by a 
central cavity) Nano-
capsule (membrane 
of simple layer)  
Polymerosome 
(membranic bilayer)  
Drug 
delivery, 
nano- 
encapsulation 
for food 
flavouring  
 Table 2  
In vitro NP toxic effects   Pathophysiological outcomes  
ROS generation  
 
Protein, DNA and membrane injury, 
oxidative stress  
  
Oxidative stress  
Phase II enzyme induction, 
inflammation, mitochondrial perturbation  
  
Mitochondrial perturbation  
Inner membrane damage, permeability 
transition, pore opening, energy failure, 
apoptosis, apo-necrosis, cytotoxicity  
  
Inflammatory response  
Tissue infiltration with inflammatory 
cells, fibrosis, acute phase protein expression 
(CRP)  
Uptake by reticulo-endothelial 
system  
Asymptomatic sequestration and 
storage in liver, spleen, lymph nodes, 
possible organ enlargement and dysfunction  
Protein denaturation  
 
Loss of enzyme activity, auto-
antigenicity  
Nuclear uptake  
 
DNA damage, nucleoprotein clumping, 
autoantigens  
  
Uptake in neuronal tissue  
Brain and peripheral nervous system 
injury  
  
Endothelial dysfunction  
Atherosclerosis, thrombosis, myocardial 
infraction  
  
Altered cell cycle regulation  Proliferation, cell cycle arrest, senescence  
DNA damage  
 
Mutagenesis, metaplasia, 
carcinogenesis  
  
